The deal size was increased to $403M in common stock from $300M in common stock. Jefferies, Goldman Sachs, Evercore ISI and Guggenheim acted as joint book running managers for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics price target raised to $90 from $65 at Baird
- Spyre Therapeutics price target raised to $90 from $50 at Wells Fargo
- Spyre Therapeutics price target raised to $88 from $55 at Deutsche Bank
- Closing Bell Movers: Bloom Energy spikes on expanded Oracle deal
- Spyre Therapeutics announces $300M offering of common stock